Core Insights - The animal health sector experienced a significant increase of 3.86% on August 15, with Shenlian Biological leading the gains [1] - The Shanghai Composite Index closed at 3696.77, up 0.83%, while the Shenzhen Component Index closed at 11634.67, up 1.6% [1] Stock Performance - Shenlian Biological (688088) saw a closing price of 10.69, with a remarkable increase of 19.98% and a trading volume of 435,300 shares, amounting to a transaction value of 441 million yuan [1] - Other notable performers included: - Biological Shares (600201) with a closing price of 8.93, up 6.06% [1] - Ruipu Biological (300119) with a closing price of 22.78, up 5.56% [1] - KQ Biological (688526) with a closing price of 17.24, up 2.44% [1] Capital Flow - The animal health sector saw a net inflow of 49.48 million yuan from institutional investors, while retail investors contributed a net inflow of 40.08 million yuan [1] - Notably, retail funds experienced a net outflow of 89.56 million yuan [1] Detailed Capital Flow Analysis - Shenlian Biological had a net inflow of 54.78 million yuan from institutional investors, while it faced a net outflow of 41.10 million yuan from speculative funds [2] - Biological Shares had a net inflow of 14.26 million yuan from institutional investors, with a net outflow of 33.08 million yuan from speculative funds [2] - Ruipu Biological recorded a net inflow of 1.78 million yuan from institutional investors, while speculative funds saw a net outflow of 16.93 million yuan [2]

Core Viewpoint - The company, Reap Bio (瑞普生物), and its wholly-owned subsidiaries have recently received new veterinary drug registration certificates from the Ministry of Agriculture and Rural Affairs for two new veterinary drugs [1] Group 1 - The new veterinary drugs include Avian Adenovirus (Group I, Type 4) Egg Yolk Antibody and Soluble Penicillin V Potassium [1] - The registration certificates were issued on August 14, indicating a significant regulatory milestone for the company [1]

Group 1 - The core point of the article is that Reap Bio (300119.SZ) has received new veterinary drug registration certificates from the Ministry of Agriculture and Rural Affairs for its products, which include avian adenovirus (Group I, Type 4) yolk antibodies and penicillin V potassium soluble powder [1] Group 2 - The new veterinary drugs are in compliance with the "Veterinary Drug Management Regulations" and the "Veterinary Drug Registration Measures" [1] - The registration was granted to Reap Bio and its wholly-owned subsidiaries, Reap (Tianjin) Biopharmaceutical Co., Ltd. and Reap (Baoding) Biopharmaceutical Co., Ltd. [1]

Core Viewpoint - The company, Reap Bio (300119.SZ), has recently received two new veterinary drug registration certificates from the Ministry of Agriculture and Rural Affairs, indicating a significant advancement in its product offerings in the animal health sector [1] Group 1: Product Details - The first product is an avian adenovirus (Group I, Type 4) yolk antibody, which is primarily used for the prevention and treatment of chicken pericardial effusion-hepatitis syndrome caused by Group I Type 4 avian adenovirus. It has the ability to neutralize the virus, alleviate hepatocyte necrosis and pericardial effusion, and promote the recovery of organ function [1] - The second product is soluble penicillin V potassium powder, which is mainly used to treat necrotic enteritis in chickens caused by Clostridium perfringens. It features a one-day withdrawal period and a zero-day egg discard period, providing core advantages in reducing drug residue risks and ensuring chicken meat food safety [1]

I 群 4 型禽腺病毒（FAdV-4）是引起鸡心包积液-肝炎综合征（安卡拉病）的 一种高致死性传染病，其潜伏期短、传播快，死亡率高达 30%-80%，对 3～6 周 龄商品肉鸡、蛋雏鸡和后备鸡养殖危害严重。 证券代码：300119 证券简称：瑞普生物 公告编号：2025-062 瑞普生物股份有限公司 关于取得新兽药注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 根据《兽药管理条例》和《兽药注册办法》的规定，瑞普生物股份有限公司 （以下简称"公司""瑞普生物"）及全资子公司瑞普（天津）生物药业有限公 司、瑞普（保定）生物药业有限公司近日获得由农业农村部核发的《新兽药注册 证书》，详情如下： | 新兽药名称 | 研制单位 | 类别 | 新兽药注册证号 | | | --- | --- | --- | --- | --- | | 禽腺病毒（I 群， | 瑞普生物股份有限公司、天津瑞普生物 | | （2025）新兽药 | | | 4 型）蛋黄抗体 | 技术股份有限公司空港经济区分公司、 | 三类 | 证字 80 | 号 | | | 瑞普（保定）生物药业有 ...

Investment Rating - The report does not explicitly state an investment rating for the animal health industry, but it highlights potential growth areas such as pet pharmaceuticals and international expansion [1]. Core Insights - The animal health industry is experiencing a slowdown in growth, with increasing competition leading to a "Matthew Effect" where larger companies gain more market share at the expense of smaller firms [3][39]. - The industry is shifting back to a research and development-driven model, with innovation becoming crucial for future growth [4][83]. - The pet pharmaceutical market and international expansion are identified as key areas for long-term growth, with pet medical consumption projected to reach approximately 84 billion yuan in 2024 [5][78]. Summary by Sections 1. Overview of the Animal Health Industry - The animal health industry, also known as the veterinary drug industry, includes a wide range of products such as vaccines, antibiotics, and feed additives [11][12]. - The market size has grown from 50.395 billion yuan in 2019 to 69.651 billion yuan in 2023, with a CAGR of 8.43% [3][12]. 2. Increasing Competition and Market Dynamics - The industry is facing a slowdown in growth, with sales increasing from 62.095 billion yuan in 2020 to 69.651 billion yuan in 2023, while average gross profit has decreased from 21.998 billion yuan to 21.297 billion yuan [3][39]. - The "Matthew Effect" is evident as larger companies leverage their product portfolios and R&D investments to capture more market share [3][52]. 3. Shift Towards R&D and Innovation - The industry is moving away from its cyclical nature, with a focus on integrated strategies and innovation to counteract competitive pressures [4][69]. - The average profit per head in self-breeding pig farming is expected to improve significantly in 2024, indicating potential for recovery in related sectors [4][62]. 4. Growth Opportunities in Pet Pharmaceuticals and Exports - The pet medical market is projected to grow rapidly, with a significant increase in demand for preventive care and treatment as pet owners become more health-conscious [5][78]. - The report highlights the successful export of domestic pet pharmaceuticals, marking a breakthrough in international markets [5][78]. 5. Key Companies to Watch - Companies such as 瑞普生物 (Reap Bio), 科前生物 (KQ Bio), and 回盛生物 (Hui Sheng Bio) are recommended for attention due to their innovative approaches and market positioning [6].

Market Overview - The animal health sector experienced a decline of 0.53% on August 13, with Dayu Biological leading the drop [1] - The Shanghai Composite Index closed at 3683.46, up 0.48%, while the Shenzhen Component Index closed at 11551.36, up 1.76% [1] Individual Stock Performance - Key stocks in the animal health sector showed varied performance, with Xianfeng Holdings closing at 3.78, up 0.53%, and Dayu Biological closing at 9.84, down 3.15% [2][1] - Other notable stocks included Jinhe Biological at 7.45, down 3.12%, and Zhongmu Co. at 7.56, down 0.66% [2][1] Trading Volume and Value - The trading volume for Xianfeng Holdings was 268,700 shares with a transaction value of 102 million yuan, while Dayu Biological had a trading volume of 46,200 shares and a transaction value of 45.92 million yuan [2][1] Capital Flow Analysis - The animal health sector saw a net outflow of 175 million yuan from institutional investors, while retail investors contributed a net inflow of 143 million yuan [2][3] - The capital flow for specific stocks indicated that Hai Li Biological had a net inflow of 2.28 million yuan from institutional investors, while Xianfeng Holdings experienced a significant net outflow of 11.02 million yuan [3][2]

Investment Rating - The overall industry rating is "Positive" for the agriculture sector, indicating expected returns above the CSI 300 index by more than 5% in the next six months [6][51]. Core Views 1. **Livestock Industry Chain** - The swine market is experiencing rising epidemic risks and policy support, which is expected to enhance the motivation for capacity reduction. The average price of live pigs is currently 13.71 CNY/kg, down 0.62 CNY from last week, while the average price for 15 kg piglets is 31.24 CNY/kg, down 1.48 CNY [5][19]. - The operating rate of large-scale slaughterhouses has increased to 31.9%, up 0.36 percentage points from last week and 7.26 percentage points year-on-year. The total output of pigs from 16 listed companies reached 100.75 million heads, a year-on-year increase of 16.9% [5][19]. - The number of breeding sows has decreased to 40.43 million heads, down 370,000 from the peak last year. The average profit per head for self-bred pigs is 45 CNY, an increase of 2 CNY from last week [6][20]. 2. **Poultry Industry** - Chicken prices are experiencing fluctuations, with the average price for broiler chickens at 3.54 CNY/lb, up 0.13 CNY from last week. The average price for white feather chickens is 13.9 CNY/kg, up 0.2 CNY [21][23]. - The industry is at a historically high capacity level, with limited imports in the first seven months of the year. The profitability per chicken has turned positive at 0.62 CNY [21][23]. - The yellow chicken market is also seeing price declines, with average prices at 9.77 CNY/kg for Lihua yellow chicken, down 0.02 CNY from last month [23][24]. 3. **Seed and Planting Industry** - The seed industry is benefiting from ongoing policy optimization and the promotion of genetically modified organisms (GMOs). The long-term investment value of leading seed companies is highlighted as they are at historical low valuations [10][24]. - Grain prices are experiencing short-term adjustments but are expected to rise in the medium term due to reduced imports and adverse weather conditions. The average purchase price for corn is 2441 CNY/ton, down 4 CNY from last week [12][24]. Company Recommendations - Recommended companies include: - Zhongchong Co., Ltd. - Buy [3] - Muyuan Foods Co., Ltd. - Buy [3] - Suqian Agricultural Development Co., Ltd. - Buy [3]

Group 1 - The company, Ruipu Biological Co., Ltd., has announced the convening of its fourth extraordinary general meeting of shareholders for the year 2025, scheduled for August 25, 2025, at 14:30 [1] - Shareholders registered by the close of business on August 18, 2025, are entitled to attend the meeting and may appoint proxies to vote on their behalf [2] - The meeting will include non-cumulative voting proposals, and the results will be disclosed separately for small investors [5][10] Group 2 - Registration procedures for attending the meeting vary for corporate and individual shareholders, with specific documentation required for each [3][6] - Shareholders can participate in voting through both on-site and online platforms, with detailed instructions provided for the online voting process [7][8] - The company has provided contact information for inquiries related to the meeting, including phone and email details [7]

Group 1 - The company held its 21st temporary meeting of the fifth supervisory board on August 8, 2025, to discuss the continuation of its asset pool business [1][2] - The supervisory board believes that continuing the asset pool business will enhance the efficiency and returns of the company's assets, benefiting long-term development without harming the interests of the company and minority shareholders [1][2] - The company plans to engage in asset pool business with a total amount not exceeding 100 million RMB and provide guarantees, in compliance with relevant regulations [2] Group 2 - The voting results for the proposal were 3 votes in favor, 0 against, and 0 abstentions, indicating unanimous support from the supervisory board [2] - The proposal will be submitted for approval at the shareholders' meeting [2]